Brand
FranceGermanyHealthcareRegional NewsUnited Kingdom

Healthcare company expands its services in Europe

Healthcare company expands its services in Europe

Precision for Medicine, part of Precision Medicine Group, has announced it is expanding its biomarker data management and translational informatics services into Europe. The addition of a Geneva, Switzerland-based team of experts complements Precision’s US offerings to provide clients with truly global translational research services. The Geneva team also gives Precision another European operational base, continuing Precision’s active international expansion.

At the forefront of precision medicine, biomarker research has become critical to the development of innovative treatments, including predicting relevant clinical outcomes across a variety of treatments and populations. However, researchers continue to struggle to organise and interrogate these highly dense and expansive data sets.

Precision’s new Geneva team is a unique and diverse group of experienced data scientists, computational biologists, computational immunologists, and translational informaticians. These computational and data science experts join Precision’s existing translational informatics team to provide unrivalled biomarker data management and translational informatics services. These services facilitate translational research for innovative pharma and biotech clients, both in Europe and the United States. Dr. Jerome Wojcik was named Senior Vice President, Translational Informatics and Biometrics, Europe, and will lead the new team in Switzerland.

The Geneva office, along with established offices in Berlin, Paris, and Edinburgh, strategically expands Precision’s growing European footprint and further positions the company as a scientific front runner in the rapidly expanding precision medicine space.

Precision is also pleased to announce the release of QuartzBioSM, the next generation of its proprietary technology platform designed to accelerate translational research. Initially launched in 2014, this latest iteration represents a significant advancement in the support of biomarker data management and translational informatics and actively supports a diverse client base of biopharmaceutical customers.

QuartzBioSM assimilates all biomarker data with extreme speed including high-content to high-throughput data, such as immunosequencing, flow cytometry, and profiling of the transcriptome, and is capable of harmonising more than 10 million data points. The first-in-class interactive platform is 21 CFR Part 11 and CDISC compliant to enable support of regulatory submissions and offers advanced visualisation and reporting capabilities, ultimately saving clients valuable time and effort.

Commenting on Precision’s expanded European capabilities and release of QuartzBioSM, Chad Clark, President of Precision for Medicine, said: “We are very excited to be expanding our translational research offering into Europe with the addition of our Geneva office. The unique diversity and scientific expertise of the team is tremendously valuable for our clients. Our global teams together with our technology platform, QuartzBioSM, create a distinctly comprehensive, industry-leading biomarker data management and translational informatics offering for international pharmaceutical innovators who are grappling every day with how best to harmonise and assess highly complex biomarker information.”